93 related articles for article (PubMed ID: 20143449)
1. Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study.
Thomas X; Raffoux E; Renneville A; Pautas C; de Botton S; Terre C; Gardin C; Hayette S; Preudhomme C; Dombret H
Cancer; 2010 Apr; 116(7):1725-32. PubMed ID: 20143449
[TBL] [Abstract][Full Text] [Related]
2. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
Löwenberg B; van Putten W; Theobald M; Gmür J; Verdonck L; Sonneveld P; Fey M; Schouten H; de Greef G; Ferrant A; Kovacsovics T; Gratwohl A; Daenen S; Huijgens P; Boogaerts M; ;
N Engl J Med; 2003 Aug; 349(8):743-52. PubMed ID: 12930926
[TBL] [Abstract][Full Text] [Related]
3. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.
Thomas X; Raffoux E; Botton Sd; Pautas C; Arnaud P; de Revel T; Reman O; Terré C; Corront B; Gardin C; Le QH; Quesnel B; Cordonnier C; Bourhis JH; Elhamri M; Fenaux P; Preudhomme C; Michallet M; Castaigne S; Dombret H
Leukemia; 2007 Mar; 21(3):453-61. PubMed ID: 17252021
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo effects of rh GM-CSF in acute myeloid leukemia (AML).
Wörmann B; Hiddemann W; Frisch J; Zühlsdorf M; Rottmann R; Boeckmann A; Reuter C; Freire EA; Innig G; Schulz G
Behring Inst Mitt; 1991 Dec; (90):28-38. PubMed ID: 1801688
[TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of priming with granulocyte macrophage colony-stimulating factor plus all-trans retinoic acid combined with remission induction chemotherapy in patients with acute myeloid leukemia.
Shin HJ; Chung JS; Choi YJ; Cho GJ
Am J Clin Oncol; 2009 Jun; 32(3):227-32. PubMed ID: 19433969
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic growth factors in acute myeloid leukemia: supportive and priming effects.
Büchner T; Hiddemann W; Wörmann B; Zühlsdorf M; Rottmann R; Innig G; Maschmeier G; Ludwig WD; Sauerland MC; Heinecke A
Semin Oncol; 1997 Feb; 24(1):124-31. PubMed ID: 9045298
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
9. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
10. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
Bruserud O; Foss B; Petersen H
Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
[TBL] [Abstract][Full Text] [Related]
12. GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly.
Pierri I; Clavio M; Beltrami G; Cavaliere M; Lanza L; Miglino M; Canepa L; Pietrasanta D; Ballerini F; Quintino S; Gatto S; Celesti L; Carrara P; Varese P; Gobbi M
J Exp Clin Cancer Res; 1999 Mar; 18(1):55-60. PubMed ID: 10374678
[TBL] [Abstract][Full Text] [Related]
13. New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.
Hiddemann W; Wörmann B; Reuter C; Schleyer E; Zühlsdorf M; Böckmann A; Büchner T
Semin Oncol; 1994 Dec; 21(6 Suppl 16):33-8. PubMed ID: 7528449
[TBL] [Abstract][Full Text] [Related]
14. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer.
Honkoop AH; Luykx-de Bakker SA; Hoekman K; Meyer S; Meyer OW; van Groeningen CJ; van Diest PJ; Boven E; van der Wall E; Giaccone G; Wagstaff J; Pinedo HM
Oncologist; 1999; 4(2):106-11. PubMed ID: 10337380
[TBL] [Abstract][Full Text] [Related]
15. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia.
Bug G; Koschmieder S; Krauter J; Heuser M; Thol F; Wiebe S; Hofmann WK; Klein SA; Wegener G; Göhring G; Heit W; Hoelzer D; Ganser A; Ottmann OG
Ann Hematol; 2014 Feb; 93(2):193-202. PubMed ID: 23978944
[TBL] [Abstract][Full Text] [Related]
17. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
Zittoun R; Suciu S; Mandelli F; de Witte T; Thaler J; Stryckmans P; Hayat M; Peetermans M; Cadiou M; Solbu G; Petti MC; Willemze R
J Clin Oncol; 1996 Jul; 14(7):2150-9. PubMed ID: 8683249
[TBL] [Abstract][Full Text] [Related]
19. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.
Bernstein SH; Christiansen NP; Fay JP; Brown R; Herzig R; Frankel S; Blumenson L; Herzig GP
Exp Hematol; 1996 Oct; 24(12):1363-8. PubMed ID: 8913281
[TBL] [Abstract][Full Text] [Related]
20. [Enhanced sensitivity to cytosine arabinoside by combined stimulation of steel factor and GM-CSF in a factor-dependent leukemic cell line, MO7e--in terms of a possible clinical application to AML treatment].
Gotoh A; Kawanishi Y; Kurosawa K; Miyazawa K; Ohtaka M; Aizawa S; Kimura Y; Yoshikawa O; Toyama K
Rinsho Ketsueki; 1993 Jul; 34(7):821-8. PubMed ID: 7689660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
